The US FDA is intensifying the spotlight on stem cell clinics, warning them that the discretionary period to determine whether they need to submit treatments as new products requiring a BLA will end soon enough and stepped up scrutiny will soon follow.
As part of its larger regenerative medicine policy framework, FDA is exercising regulatory discretion to allow firms up to November...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?